Review

Future approaches for treating Chronic Myeloid Leukemia: CRISPR therapy

Elena Vuelta 1, Ignacio García-Tuñón 2, Patricia Hernández-Carabias 1, Lucía Méndez 1 and Manuel Sánchez-Martín 1, 2, *

1 Departamento de Medicina, Universidad de Salamanca, Spain.
2 Instituto de Investigación Biomédica de Salamanca (IBSAL), Spain
* Correspondence: adolsan@usal.es (MSM)

Summary: The constitutively active tyrosine kinase BCR/ABL1 oncogene plays a key role in human chronic myeloid leukemia development and disease maintenance, and determines most of the features of this leukemia. For this reason, tyrosine kinase inhibitors are the first-line treatment, offering most patients a life expectancy like that of an equivalent healthy person. However, since the oncogene is not destroyed, lifelong oral medication is essential, even though this trigger adverse effects in many patients. Furthermore, leukemic stem cells remain quiescent and resistance is observed in approximately 25% of patients. Thus, new therapeutic alternatives are still needed. In this scenario, the emergence of CRISPR technology can offer a definitive treatment based on its capacity to disrupt coding sequences. This review describes CML disease and the main advances in the genome-editing field by which it may be treated in the future.

Keywords: CML, CRISPR/Cas9, BCR/ABL1, genome editing.

1. Clinical features of chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative disease with an incidence of 1-2 cases per 100,000 each year accounting for 15% of all new cases of leukemia [1]. The frequency is higher among adults, in whom the mean age of incidence is about 55 years, and indeed, rarely arises during childhood. It may affect both sexes, but is slightly more common in males, with a ratio of 2.2 men to 1.4 women per 100,000 affected [2,3]. The most common clinical symptoms of CML include fatigue, anemia, splenomegaly, abdominal pain, and recurrent infections. However, a large proportion of asymptomatic patients are diagnosed after an unrelated medical examination [1]. Three clinical phases of its pathological evolution are recognized. At first, CML disease is characterized by a myeloid hyperplasia in an indolent chronic phase (CP). At this point, leukemic stem cells (LSCs) respond to growth factors, but myeloproliferative differentiation pathways acquire an advantage because they are the main cause of the massive myeloid expansion characteristic of CML [4]. In this initial phase, myeloid progenitors and mature cells accumulate in the blood and extramedullary tissues. Without effective therapy, CML progresses through a period of increasing instability known as the acceleration phase (AP), ending in an acute leukemic-like disease known as the blast crisis phase (BP). The definitions of AP and BP are largely dependent on the proportion of blasts in the blood and bone marrow. AP and BP are characterized by a maturation arrest in the myeloid or lymphoid lineage, and newly accumulated genetic and epigenetic aberrations occur in LSCs [5]. The final BP stage can result in a lymphoblastic (25%), myeloblastic (50%) or biphenotypic/undifferentiated acute leukemic phenotype (25%), which indicates a stem origin for CML disease [6] (Figure 1). Finally, bone marrow failure due to a lack of cell differentiation, and a massive infiltration by immature blasts causes patient mortality from infection, thrombosis, or anemia [7].
Diagnosis is based on detecting the hallmark of CML, the presence of the chromosome 22 abnormality known as Philadelphia (Ph), named after the US city in which it was first observed. It is the result of the reciprocal translocation between chromosomes 9 and 22 -t(9;22)- [8]. Conventional cytogenetics, fluorescent in situ hybridization (FISH), and reverse transcriptase PCR (RT-PCR) are the techniques commonly used to confirm a diagnosis of CML and to evaluate the response to therapy.

Before successful treatments became available, the median survival of CML patients after diagnosis was approximately 3-5 years [9,10]. The therapeutic landscape of CML changed profoundly with the introduction of TKI drugs [9,11,12] and most patients with CP-CML now have a normal life expectancy. However, treatment discontinuation is only an option for a small subset of patients [13].

2. Molecular biology of chronic myeloid leukemia

Nowell and Hungerf, in 1960, first described the Ph chromosome, a small chromosome present in the bone marrow cells of CML patients [8]. It was the first time that a chromosomal abnormality had been linked to a particular neoplasia [14]. Subsequent investigations confirmed that the generation of the Ph chromosome was due to the t(9;22)(q34;q11) translocation. The next breakthrough in our understanding of CML occurred in the 1980s, when it was demonstrated that this rearrangement gave rise to a fusion gene [15]. In this translocation, the analogue of the v-ABL protooncogene from chromosome 9 is moved to the breakpoint cluster region of the BCR gene on ch22. The location of the breakpoints between the two loci is variable [16]. Commonly, the breakpoint at the ABL locus occurs in a DNA region spanning more than 200 kb housing exon 2. At the BCR locus, the breakpoints occur in the major breakpoint cluster region (M-bcr), which spans a 3-kb region that includes exons 13 and 14 of BCR. All the rearrangements involving both breakpoint regions give
rise to a 210-kDa protein, the most common chimeric transcript in CML [17]. However, in a minority of CML cases, the BCR breakpoint is located near exon 2, termed the minor breakpoint cluster region (m-bcr). In these cases, the resulting mRNA gives rise to a 190-kDa protein [16]. Finally, another infrequent breakpoint cluster region (μ-bcr) exists, downstream of BCR exon 19, which generates a 230-kDa protein when it is translocated to the ABL1 locus [18] (Figure 2).

Figure 2. Structure of the BCR/ABL1 oncogene. A. Schematic representation of the t(9;22)(q34;q11) translocation triggering the Philadelphia chromosome. B. Breakpoint locations between BCR and ABL1 genes. Different fusion protein combinations yield different outcomes.

Since the BCR/ABL1 fusion was described, the efforts of the scientific community have focused on elucidating its molecular roles in CML pathology. Several studies have shown the aberrant and constitutive tyrosine kinase activity of the BCR/ABL1 oncoprotein, highlighting this activity as being responsible for the transformation of the hematopoietic stem cell [19–22]. The fusion of the two genes constitutively activates the tyrosine kinase domain of ABL1, which contains three SRC homology domains (SH1-SH3). The SH1 domain enables the tyrosine kinase function, whereas the SH2 and SH3 domains mediate interactions with other proteins [23]. The SH3 domain is critical to the regulation of ABL1 kinase activity, enabling the binding of inhibitory molecules. It is known that the fusion between the 5' end of BCR and the SH3 domain of ABL1 abrogates the physiological suppression of the kinase [24]. Meanwhile, BCR has an important coiled-coil (CC) domain that will allow BCR/ABL1 dimerization and subsequent trans-autophosphorylation, thus increasing the molecular signal [25] (Figure 3). The phosphorylation of the Y-177 tyrosine residue domain SH2 of ABL allows the high-affinity binding of the growth factor receptor-bound protein 2 (GRB2) as well as the scaffolding protein Gab2, activating the Ras pathway [26]. This aberrant kinase signaling activates many target proteins, such as the PI3K, AKT, JNK, and SRC family kinases, as well as transcription factors such as STATs, nuclear factor-κB and MYC [27–29]. The constitutively active signaling causes cell reprogramming and expansion of the LSC clone. As a result, BCR/ABL1-positive hematopoietic stem cells exhibit uncontrolled proliferation [30], lack of response to apoptotic signals [31], alterations in...
cell adhesion [32], impaired differentiation [33], and independence of growth factors [34]. As a consequence, a myeloid differentiation bias is commonly observed in the chronic phase of CML.

Figure 3. BCR/ABL protein domains. Protein regions located in the BCR (A) and ABL (B) proteins, and those maintained in the fusion (C). The figure highlights the coiled-coil (CC) domain of BCR, which allows the dimerization of the oncoprotein, and the three SRC domains of ABL1, including the tyrosine kinase domain (SH1) and the regulatory domains (SH2 and SH3).

3. Conventional therapies for chronic myeloid leukemia

The history of CML treatment can be considered one of the great milestones of modern cancer medicine. From its discovery until the 1980s, the standard treatment for CML consisted of conventional chemotherapy. Arsenic was the first treatment to be administered, in the 19th century, but was superseded by alkylating drugs such as busulfan and hydroxyurea in the 1960s [35,36]. Unfortunately, they did not delay the onset of disease progression and facilitated only a modest improvement in survival. The introduction of interferon-α in the 1970s induced complete cytogenetic remission in 10–15% of patients, and increased median survival to 6 years [37]. However, interferon-α treatment has serious side-effects, and treatment had to be discontinued in most patients, causing them to relapse. In this context, allogenic stem cell transplantation (SCT) was the only therapeutic option that could provide increased long-term survival, and so it became the first-line treatment in the 1990s for patients in the chronic phase [38–40]. Even today, this therapeutic option is the only one with the potential to definitively cure CML patients in this phase. The SCT procedure involves bone marrow ablation (by chemotherapy or radiotherapy) followed by the infusion of normal allogenic stem cells. However, it is only available to a small number of patients who have an HLA-matched donor, and is associated with a significant transplant-related mortality rate [40]. Nowadays, SCT is used solely as a last-resort salvage option.

As mentioned above, CML is a type of cancer in which all the pathological features can be attributed to a single genetic event, in this case the BCR/ABL1 fusion. Knowing that the tyrosine kinase activity of BCR/ABL1 is essential for the malignant transformation of cells, the search for compounds that inhibit this activity became imperative. During the 1990s, various tyrosine kinase inhibitors (TKIs) were tested to evaluate their therapeutic potential in CML [41,42]. The mechanism of action of these compounds is based on competition with adenosine triphosphate (ATP) or the protein substrate of the kinase, whereby BCR/ABL1 activity is inhibited at the protein level. Finally, in the 2000s, the Novartis compound STI571 (later known as imatinib mesylate), which showed surprising results by selectively inhibiting BCR/ABL1 at micromolar concentrations, was approved
as therapy for CML [43,44]. The arrival of TKIs marked a watershed in the treatment of CML and they remain the frontline therapy for LMC. Thanks to TKIs, CP-CML patients, who, before 2001, had a survival rate of 20% at 8 years, now have a rate of 87%, and a life expectancy like those of healthy people of the same age [11,12,18].

Despite the success achieved with TKI-based treatments, there are still obstacles to overcome. The main concern is that TKI drugs do not tackle the etiological cause of CML and the oncogenic event remains uncorrected or destroyed. The existence of residual BCR/ABL-positive cells, which remain “oncogenic-quiescent”, has been demonstrated, indicating that TKIs do not completely eliminate the LSCs [45]. TKIs efficiently silence the oncogenic activity of BCR/ABL while the drug is present, but the remaining LSCs can lead to relapse after TKI therapy ceases (Figure 4). In this scenario, lifelong oral medication is necessary, and treatment discontinuation is only an option in those patients who were able to achieve and maintain strong molecular responses. Lifelong administration facilitates adverse effects in many patients and a significant percentage of them eventually become resistant to TKI treatment [46]. The identification of various forms of resistance has led to the development of second- and third-generation TKIs that are effective against kinase-specific mutations in these patients [47].

Figure 4. Conventional therapies vs. gene therapy for CML. Tyrosine-kinase inhibitor (TKI)-based conventional therapies are effective at silencing BCR/ABL1 in leukemic stem cells (LSCs). Treatment cessation can lead to relapse because of the existence of residual BCR/ABL1-positive cells. The appearance of TKI-resistant LSCs during treatment can lead to a relapse of the disease. However, anti-BCR/ABL1 gene therapy would eliminate the oncogene at the genome level. Corrected LSCs would be able to repopulate the bone marrow niche and thereby enable normal haematopoiesis.

Taking this therapeutic scenario into account, it is still necessary to seek new and definitive alternative therapies. Currently, any coding sequence can be abolished by CRISPR/Cas9 nucleases [48–50] or zinc finger nuclease [51], which means there is an opportunity of a definitive cure available to TKI-resistant CML patients. Thus, CRISPR/Cas9 system could be a definitive therapeutic option.
4. Genome-editing nucleases for gene therapy

Advances in molecular biology and genetics in recent years have broadened our knowledge of genetically based diseases, and very many genes involved in their development have been identified. These same advances have made it possible to develop the genome-editing technology with which these candidate genes can be genetically manipulated. With the advent of engineered chimeric proteins with nuclease activity, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), genome manipulation has become more feasible than ever [52,53]. These new approaches overcome the difficulties associated with previous genome-editing techniques based on homologous recombination (HR), such as low efficiency, laborious and time-consuming assays [54]. The mechanism of action of genome-editing nucleases is based on the generation of double-strand breaks (DSBs) in the DNA that stimulate the endogenous cellular DNA repair mechanisms: non-homologous end-joining (NHEJ) and homology-directed repair (HDR). NHEJ results in the introduction of random insertion or deletion (indel) mutations that, in a coding sequence, most frequently lead to frameshift mutations that generate null alleles. The HDR pathway exploits the phenomenon of homologous recombination specifically to introduce an exogenous donor DNA template in the DSB site, allowing mutated sequences to be replaced or edited [55] (Figure 5). ZFN and TALEN have been widely used for decades, but the proteinaceous nature of their structure leads to serious technical drawbacks, such as the complexity of design and high costs [56]. Fortunately, the recent development of the CRISPR/Cas9 system in the genome-editing field has revolutionized this methodology. The simplicity of this system offers a powerful, effective, low-cost, and universal tool heralding a new era for gene therapy.

![Double-Strand Break (DSB)](image)

**Figure 5.** The NHEJ mechanism involves the action of the proteins ku70/80, DNA-PKcs and Artemis, with the ability to bind to the free DNA ends that are generated. The resected DNA ends are joined by the action of ligase IV with the insertion of a variable number of nucleotides (indels) that, in most cases, lead to the generation of null alleles. The HDR pathway begins with the resection of the released DNA ends. The RPA, Rad51 and BRCA2 proteins act by binding and protecting the ssDNA that is generated. Through homologous recombination, the HDR pathway allows the introduction of DNA templates from exogenous donors at the DSB site, replacing the target genomic sequence.

5. Overview of the CRISPR/Cas9 system

In 1993, Mojica et al. described for the first time a matrix of tandem-repeated sequences, interspersed with another type of flanking sequence, which was formally named as Clustered...
Regularly Interspaced Short Palindromic Repeats (CRISPR) [57]. Some years later, it was discovered that these unknown spacer sequences had a high percentage of similarity with sequences found in various types of bacteriophages and plasmids [58]. Finally, in 2007, Barrangou et al. demonstrated that the CRISPR system was a rudimentary prokaryotic immune system that protects prokaryotes against foreign DNA infections [59]. CRISPR and their associated proteins (Cas) provide an adaptive immune system that integrates short genomic sequences of invaders, named spacers, into the CRISPR locus. The different spacers are interspersed with tandem sequences and are expressed as small guide CRISPR RNAs (crRNAs) that drive the Cas proteins to cleave the invader genome [60]. crRNAs are employed by the Cas nuclease to match with invading nucleic acids in a sequence specific fashion. Finally, the transactivating CRISPR RNA (tracrRNA) completed the puzzle to clarify the nature of Cas9 activity [61]. The tracrRNA is a scaffold that partially hybridizes with the crRNA and the Cas9 endonuclease, allowing all the components to be assembled [50]. Importantly, the only requirement for Cas nuclease activity is the existence of a small PAM motif (protospacer adjacent motif) at the 3' end of the target sequence (Figure 6). These discoveries and the demonstration of their in vitro activity [50] opened the door to using this system as a genome-editing nuclease. Its simplicity, effectiveness and universality mean that the CRISPR/Cas9 system has rapidly become the preferred tool for RNA-guided genome editing. In fact, it has been widely applied for gene modification in several model systems [62-66]. It is likely that the CRISPR/Cas9 system will be incorporated into the therapeutic strategy for the treatment of monogenically inherited disorders and malignancies whose pathological features can be attributed to a single genetic event, such as gene fusion [67].

6. CRISPR gene therapy in CML

In the last five years, the number of scientific papers reporting work on CRISPR/Cas9 in the context of leukemia research has increased enormously [67–71]. Many of them concern in vitro studies to clarify the role of a variety of genes in leukemia development [72]. These studies identify key genes that will subsequently be edited in leukemic cells using CRISPR/Cas9 technology. In 2015, Valletta et al. demonstrated for the first time that the CRISPR/Cas9 system could correct acquired mutations in a human myeloid leukemia cell line [73]. CRISPR-Cas9 was then successfully used in animal models of genetic diseases. Finally, the first clinical trials involving CRISPR-Cas9 in humans were initiated in 2016 [74]. Focusing on hematopoietic stem cells (HSCs), the first clinical trial to treat thalassemia (NCT03655678) using CRISPR-Cas9-modified HSCs was approved in 2018 [75]. In this sense, CML could also be one of the best candidates with which to evaluate the therapeutic potential of CRISPR/Cas9 system. CML is an HSC malignancy directed by a single oncogene. The singularities of HSCs, which sustain the long-term generation of all hematopoietic lineages, make CML an ideal candidate for gene therapy. The special characteristics of self-renewing and multipotent HSCs imply that gene-editing or ablation by CRISPR will be inherited by all daughter cells, restoring a new hematopoiesis. Furthermore, the peculiarities of the hematopoietic compartment, which make possible the collection and subsequent reinfusion of HSCs, enable the development of ex vivo therapies, and thereby the evaluation and selection of the edited HSCs, improving the safety and efficiency of the process. Imatinib therapy is based on the knowledge that the BCR/ABL1 fusion is the underlying cause of CML pathogenesis. For this reason, it is reasonable to surmise that the CRISPR/Cas9-induced gene interruption of BCR/ABL1 might offer a definitive cure (Table 1). The development of immunodeficient mice for human HSC engrafting [76] and of mouse models that mimic human CML [77] has provided new opportunities to evaluate these CRISPR/Cas9 therapeutic applications. Recently, several in vitro and in vivo studies have explored the ability of CRISPR/Cas9 to destroy the BCR/ABL1 gene fusion. In 2017, García-Tuñón and coworkers demonstrated for the first time that the CRISPR/Cas9 system effectively abrogates the BCR/ABL1 oncogene, reversing its tumorigenic activity [67]. They showed in a CML xenograft animal model how edited CRISPR cells lost their ability to proliferate and survive, and that no tumors developed when the edited cell was selected. Their results constituted the proof-of-principle that BCR/ABL1 abrogation by the CRISPR system results in the loss of tumorigenicity.
Figure 6. CRISPR-mediated adaptive immunity system presents in prokaryotes. After the first viral infection, the Cas complex excises the viral DNA, then introduces it into the bacterial genome. When the second viral infection occurs, a complementary RNA (crRNA) to that of the viral genome is used to guide the cas9 nuclease to degrade the viral DNA.

In 2018, Wenli Feng’s group demonstrated that other genome-editing nucleases, like ZFN nucleases, achieved the abrogation of the BCR/ABL1 oncogene [71]. Using a pair of ZFNs targeting the exon 1 of BCR, a premature stop codon was created that was capable of generating a truncated oncoprotein. The apoptotic rate was higher and the proliferative capacity was lower in the ZFN-edited cells. The same group published a subsequent study in which they overcame the technical limitations linked to the use of the ZFNs [70]. The authors adopted a new strategy based on CRISPR RNA-guided FokI nucleases (RFNs) to target exon 2 of ABL1. According to them, the combination of the universality of the CRISPR site design and the specificity of the FokI cleavage would provide an efficient and secure editing tool that would avoid the limitations of previous systems such as the labor-intensive design of ZFNs and off-targets of CRISPR/Cas9. RFN-editing proved to be effective, achieving a reduction in the expression of BCR/ABL1 and its downstream targets, in the imatinib-sensitive and imatinib-resistant forms of K562. Edited cells showed a loss of their malignant potential, reflected in a depressed proliferative and colony-forming capacity in vitro. Furthermore, when these edited cells were transplanted by intravenous injection into the tail vein of NOD/SCID animals, they showed an impaired in vivo leukemogenic capacity.

Recently, new work focusing on the disruption of BCR/ABL1 by genome-editing nucleases as a therapeutic strategy in CML has revealed the therapeutic potential of CRISPR system. In 2020, Chia-Hwa Lee et al., using a CRISPR/Cas9 lentiviral vector to disrupt ABL1 in the human CML K562 cell line, demonstrated a reduced proliferation rate as a consequence of BCR/ABL1 disruption [78]. Ex vivo transduction of peripheral blood mononuclear cells from CML patients was performed to evaluate the therapeutic potential of this viral system in the clinical milieu.
**Table 1.** Therapeutic strategies to disrupt the BCR/ABL1 oncogene in CML by genome-editing nucleases.

<table>
<thead>
<tr>
<th>Target</th>
<th>Cell type</th>
<th>Genome editing system</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fusion sequence</td>
<td>Boff p210 (mouse)</td>
<td>CRISPR/Cas9</td>
<td>Subcutaneous injection of edited single cell derived clones was unable to generate tumors in a CML xenograft model.</td>
<td>[79]</td>
</tr>
<tr>
<td>BCR exon 1</td>
<td>K562 (human) and patient derived CD34+ cells</td>
<td>ZFNs</td>
<td>Intravenous tail vein injection into NOD/SCID mice of the edited K562 showed a lower tumorigenic capacity in vivo. Lower proliferative capacity in vitro was observed in edited primary cells.</td>
<td>[71]</td>
</tr>
<tr>
<td>ABL1 exon 2</td>
<td>K562 (human) and patient derived CD34+ cells</td>
<td>CRISPR RNA-guided FokI nucleases (RFNs)</td>
<td>Similar results to those of their previous work. High efficiency and greater security by reducing the frequency of off-targets, compared with CRISPR/Cas9 system.</td>
<td>[70]</td>
</tr>
<tr>
<td>ABL1 exon 2</td>
<td>K562 (human) and peripheral blood mononuclear cells (PBMCs) of CML patients</td>
<td>CRISPR/Cas9</td>
<td>Virus-mediated ABL1-targeting to edit luciferase-labeled K562 into a systemic leukemia xenograft model. Bioluminescence imaging showed a significant reduction of leukemic cells in vivo.</td>
<td>[78]</td>
</tr>
<tr>
<td>Fusion sequence</td>
<td>K562 (human) and patient derived CD34+ cells</td>
<td>CRISPR/Cas9</td>
<td>Specific targeting of the BCR/ABL1 fusion sequence with a pair of guides directed towards intronic sequences of each of the genes involved in the fusion that will cause a deletion in those cells that carry the translocation.</td>
<td>[69]</td>
</tr>
<tr>
<td>ABL1 exon 6</td>
<td>Boffp210 (mouse), K562 (human), Lin-CML mouse model and patient-derived CD34+</td>
<td>CRISPR/Cas9</td>
<td>Edited HSCs from CML mouse model restored normal hematopoiesis in NOD/SCID bone marrow niche. Edited patient-derived CD34+ are capable of regenerating normal hematopoiesis in the bone marrow niche of NOD/SCID mice.</td>
<td>[80]</td>
</tr>
</tbody>
</table>
They observed a high rate of apoptosis in the transduced cells, and demonstrated that non undesirable consequences are triggered by the disruption of the *ABL1* non-rearranged allele. The T-cell lineage was not affected by CRISPR activity at this *ABL1* non-translocated locus.

A new approach based on the use of two guides to induce a large deletion and selectively eliminate fusion oncogenes has been developed by Rodriguez-Perales and coworkers [69]. This new strategy induces a large genomic deletion in the tumor cells and shows great inhibition-specific tumor growth in a K562 xenograft model.

Finally, Vuelta et al. recently reported their design of a new CRISPR/Cas9 short-deletion system that efficiently interrupts the *BCR/ABL1* oncogene in murine/human cell lines and, for the first time, in primary leukemic stem cells (CD34+) from a CML mouse model and from human CML patients [80]. They demonstrated that CRISPR/Cas9-edited LSCs had impaired tumorigenic activity and fully restored capacity for multipotency. Further, they showed that the infusion of CRISPR/Cas9-edited LSCs confer a significant therapeutic benefit on orthotopic patient-derived xenografts (PDXs) and on CML mouse models. We revealed that CRISPR/Cas9 technology can easily be used to destroy driver oncogenes like *BCR/ABL1*, providing proof-of-principle for gene therapy through genome-editing nucleases.

7. Future directions

With the advent of genome-editing nucleases and, especially, the CRISPR/Cas9 system, the possibilities of modifying the genome of species have reached hitherto unimaginable limits. In this context, gene therapy is one of the fields that has experienced a great impulse. The possibility of definitively curing genetic diseases, by direct correction of the underlying cause of the pathology, has ceased to be a future possibility and become a current reality. However, certain limitations still hinder the use of gene therapy as part of routine medical practice. Like other gene therapy approaches, the greatest limitation of in vivo CRISPR therapy is the difficulty of finding an optimal and safe delivery method. On the other hand, the preexisting adaptive immunity to Cas9 proteins in humans [81] could be considered and new Cas proteins should be employed. The issue about CRISPR off-targets also needs to be resolved. Efforts to discover new Cas variants with high fidelity will offer a solution. Finally, despite the development of new and increasingly efficient methods, 100% editing efficiency is unattainable. However, guaranteeing the absence of unedited cells is imperative in many therapeutic hematopoietic malignancies, such as the disruption of *BCR/ABL1* in CML. A possible solution would involve the selection of the correctly edited cells, which would entail the design of genome-editing approaches that simultaneously allow the genetic correction and expression of a selectable cell marker.

In summary, the enormous therapeutic potential of the CRISPR/Cas9 tool has been widely corroborated in numerous research papers and in clinical trials. There are technical limitations associated with this technology, but the number of possible alternatives to overcome them has increased at the same rate. We are certain that CRISPR/Cas9 gene therapy will become a routine clinical practice in the near future.
breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia [Internet].
chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell [Internet].
leukemia: Low levels of p230 BCR/ABL mRNA and undetectable p230 BCR/ABL protein may predict an
indolent course. Cancer. 2002 May 1;94(9):2416–25.
19. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of
bcr-abl oncogene products. Science (80- ) [Internet]. 1990 [cited 2020 Dec 21];247(4946):1079–82. DOI:
10.1126/science.2408149
20. Kabarowski JHS, Witte ON. Consequences of BCR-ABL expression within the hematopoietic stem cell
p. 399–408. DOI: 10.1002/stem.180399
22. Janossy G, Roberts M, Greaves MF. TARGET CELL IN CHRONIC MYELOID LEUKÆMIA AND ITS
RELATIONSHIP TO ACUTE LYMPHOID LEUKÆMIA. Lancet [Internet]. 1976 Nov 13 [cited 2020 Dec
21];308(7994):1058–61. DOI: 10.1016/S0140-6736(76)90970-3
24. Mayer BJ, Baltimore D. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl
10.1128/mcb.14.5.2883
25. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the
transforming function of Bcr-Abl oncoproteins. Mol Cell Biol [Internet]. 1993 Dec [cited 2020 Dec
21];13(12):7587–95. DOI: 10.1128/mcb.13.12.7587
Pathways in Cancer Pathogenesis and Therapy [Internet]. Springer New York; 2012 [cited 2020 Dec 21].
p. 95–108. DOI: 10.1007/978-1-4614-1216-8_7
apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. Vol. 25,
73. DOI: 10.1002/j.1460-2075.1994.tb06319.x
31. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic


75. A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Dec 22].


